title: [Short bowel syndrome and intestinal failure - new developments].
abstract: Intestinal failure is characterized by intestinal water and electrolyte losses as well as malabsorption of macronutrients. It often requires individually composed parenteral support (so call compounding). Teduglutide, a DPP-IV resistant GLP2 analogue, is available a pharmacologic treatment, which stimulates intestinal absorption and can facilitate infusion free days. Catheter infections are the most common complication of home parenteral support. The incidence can be minimized using Taurolidin as a catheter block solution.
authors.affiliation: Zentrum Innere Medizin, Klinik II, Abteilung Gastroenterologie und Endokrinologie, Universitätsmedizin Rostock.
authors.forename: Georg
authors.initials: G
authors.lastname: Lamprecht
mesh_terms: D055499:Catheter-Related Infections / Q000209:etiology / Q000517:prevention & control; D019317:Evidence-Based Medicine; D006801:Humans; D007410:Intestinal Diseases / Q000175:diagnosis / Q000209:etiology / Q000628:therapy*; D008286:Malabsorption Syndromes / Q000175:diagnosis / Q000209:etiology / Q000628:therapy*; D010289:Parenteral Nutrition, Total / Q000009:adverse effects; D010455:Peptides / Q000009:adverse effects / Q000627:therapeutic use*; D012778:Short Bowel Syndrome / Q000175:diagnosis / Q000209:etiology / Q000628:therapy*; D014883:Water-Electrolyte Imbalance / Q000175:diagnosis / Q000209:etiology / Q000628:therapy*
chemical_list: D010455:Peptides; C494910:teduglutide